Browsing Tag
Ambros Therapeutics Inc.
1 post
Werewolf stock doubles as $150m Ambros merger pivots company to Phase 3 pain drug
Werewolf Therapeutics will merge with Ambros Therapeutics in an all-stock transaction that values Ambros at $500 million before financing and backs its Phase 3 neridronate program with a $150 million private placement.